Citations

Clear

1417 citation(s) found for "Li, Simon".

Multicenter Phase II Study of Olaparib and the ATR Inhibitor Ceralasertib in Metastatic Castration-Resistant Prostate Cancer (TRAP)
Tsung, Irene , Smith, David C. , Heath, Elisabeth I. , Cackowski, Frank C. , Devitt, Michael , Braun, Thomas , Yentz, Sarah , Nguyen, Charles B. , Shah, Neel , Vaishampayan, Ulka N. , Caram, Megan E.V. , Palmbos, Phillip L. , Alumkal, Joshi J. , Reichert, Zachery R. , Cackowski, Frank C , Devitt, Michael E , Braun, Thomas M , Dean, Emma , Vaishampayan, Ulka , Caram, Megan E V , Palmbos, Phillip , Alumkal, Joshi J , Reichert, Zachery R , Chinnaiyan, Arul , Smith, Simon A.

Mayo Clinic

JCO Precision Oncology | September 16, 2025 | Volume: No volume available | Issue: 9 | Pages: No page available

10.1200/po-25-00457 | PMID 40956994 Get It

PURPOSE Preclinical studies suggest the combination of the poly(adenosine diphosphate[ADP]-ribose) polymerase (PARP) inhibitor olaparib and the ataxia telangiectasia–mutated and Rad3-related (ATR) inhibitor ceralasertib has synergistic antitumor activity in homologous recombination proficient (HRP) and homologous recombination repair gene mutation (HRRm) patients. This study aims to determine the efficacy of olaparib plus ceralasertib in metastatic castration-resistant prostate cancer (mCRPC) with and without HRRm. PATIENTS AND METHODS Thirty-five HRP and 12 HRRm PARP inhibitor–naïve patients with mCRPC progressing on ≥1 line of therapy or previous androgen receptor pathway inhibitor were enrolled. Patients received olaparib (300 mg twice daily) and ceralasertib (160 mg once daily, days 1-7) in 28-day cycles. HRRm was defined as biallelic inactivation of BRCA2 or BRCA1 , monoallelic inactivation of ATM , or germline inactivation of any of these genes. The primary end point was disease response rate (dRR; confirmed prostate-specific antigen decline ≥50% and/or complete/partial radiographic response by RECIST v1.1) in HRP patients. Secondary end points included dRR in HRRm patients, progression-free survival (PFS), and safety/toxicity. Two-stage designs were used. RESULTS Four of 35 (11%; 95% CI, 3.2 to 26.7) HRP and four of 12 HRRm patients responded. Median PFS was 8.2 months (95% CI, 5.3 to not reached) for HRP patients. Thirty-six percent of patients had ≥grade 3 toxicity, most commonly from anemia. Limitations include small, single-arm, nonrandomized trial design. CONCLUSION Combining ceralasertib with olaparib had limited activity in patients with HRP mCRPC. HRRm response rate was not greater than previous single-agent PARP inhibitor clinical trials.
Biliary Tract Cancers, Version 2.2025, NCCN Clinical Practice Guidelines In Oncology
Benson, Al B. , D’Angelica, Michael I. , Ahmed, Aijaz, Akce, Mehmet , Anaya, Daniel A. , Are, Chandrakanth , Aye, Lydia, Baker, Marshall S., Binder, David C. , Burgoyne, Adam M. , Castellanos, Jason , Cloyd, Jordan M. , Franses, Joseph W. , Harris, William P., Iyer, Renuka , Jennings, Lawrence J. , Kelley, Robin Kate , Khan, Sajid , Palta, Manisha , Sahai, Vaibhav , Stein, Stacey , Stephans, Kevin L. , Thanikachalam, Kannan , Yano, Motoyo , Yopp, Adam C. , Zhao, Ken, Schonfeld, Ryan, Hochstetler, Cindy, Sahai, Vaibhav , Abrams, Thomas A. , Anders, Robert A. , Bachini, Melinda , Brown, Daniel B. , Cullinan, Darren R. , Glazer, Evan S. , Levine, Matthew H , Melstrom, Laleh , Raman, Steven S. , Ronnekleiv-Kelly, Sean M , Turk, Anita , Vauthey, Jean‐Nicolas , Venook, Alan P. , Zhao, Ken

Mayo Clinic

Journal of the National Comprehensive Cancer Network | September 10, 2025 | Volume: 23 | Issue: 9 | Pages: 403-418

10.6004/jnccn.2025.0042 | PMID 40930144 Get It

The NCCN Guidelines for Biliary Tract Cancers (BTCs) provide recommendations for the evaluation and comprehensive care of patients with gallbladder cancer, intrahepatic cholangiocarcinoma, and extrahepatic cholangiocarcinoma. The multidisciplinary panel of experts is convened at least once annually to review requests from internal and external entities as well as to evaluate new data on current and emerging therapies. This manuscript focuses on the adjuvant chemotherapy and chemoradiation treatment options for BTCs as well as the systemic treatment recommendations for patients with advanced BTCs.
Radiotherapy for Growing Vestibular Schwannomas
Sethi, Mantegh , Gowrishankar, Shravan , Mannion, Richard , Guilfoyle, Mathew R., Buttimore, Juliette , Gamazo, Nicola, Duke, Simon, Jena, Raj, Burton, Katherine , Fornezza, Umberto, Perini, Zeno, Mari, Cristina , Gazzola, Luca, Schouten, Sammy M , Kunst, Henricus P. M. , Bassi, Rohan, MacKeith, Samuel , Whitfield, Gillian , McBain, Catherine , Hotchkies, A , Lloyd, Simon , Obholzer, Rupert , Cheang, Ya Fang Amanda, Thomas, Nick, Barazi, Sinan, Maratos, Eleni, Hassan, Sheila, Tancu, Cornel, Kitchen, Neil , Marinelli, John P. , Carlson, Matthew L., Link, Michael J. , Tysome, James Russell , Donnelly, Neil P. , Axon, Patrick , Bance, Manohar , Jena, Raj, Burton, Katherine, Jefferies, Sarah , Mari, Cristina, Gazzola, Luca , Compter, Inge , Eekers, Daniëlle B. P. , Jeyaretna, Deva Sanjeeva , Colaco, Rovel J. , Shapey, Jonathan , Carlson, Matthew L. , Borsetto, Daniele

Mayo Clinic

JAMA Otolaryngology–Head & Neck Surgery | September 4, 2025 | Volume: 151 | Issue: 10 | Pages: 931

10.1001/jamaoto.2025.1953 | PMID 40906473 Get It

Importance In the literature, there is a lack of data reporting tumor control rates after radiotherapy in actively growing vestibular schwannomas (VS). Data for this rarely studied population are needed. Objective To estimate tumor control rates in radiologically growing VS treated with first-line radiotherapy. Design, Setting, and Participants This international, multicenter cohort study used prospectively collected data from patients with growing unilateral VS treated first-line with radiotherapy between January 2000 and December 2023 from 8 tertiary referral skull base units. The data were analyzed in June 2025. Exposures Radiotherapy as an initial treatment for VS. Main Outcomes and Measures The primary outcome was treatment failure, ie VS growth postradiotherapy, which was predefined as an increase in maximum intracranial tumor diameter (ICTD) of 3 mm or greater within the first 2 years after radiotherapy or 2 mm or greater thereafter. Secondary outcomes were treatment failure based on different definitions of VS growth: (1) an increase in ICTD of 2 mm or greater, (2) an increase in ICTD of 3 mm or greater, and (3) conversion to surgery. Results A total of 1883 patients (975 female individuals [51.8%]; median age at diagnosis, 63 years [IQR, 53-71 years]) were included in the study. Using the primary definition of treatment failure (an increase in ICTD of ≥3 mm within the first 2 years postradiotherapy or ≥2 mm thereafter), the Kaplan-Meier estimate yielded a 10-year tumor control rate of 76.1% (95% CI, 72.7%-79.2%). For secondary outcome definitions, 10-year tumor control rates were 60.1% (95% CI, 57.5%-64.3%) for an ICTD increase of 2 mm or greater, 78.3% (95% CI, 75.0%-81.2%) for an increase of 3 mm or greater, and 92.6% (95% CI, 90.4%-94.3%) for conversion to surgery. Neither pretreatment tumor size nor tumor location (intracanalicular vs extracanalicular) were significantly associated with treatment failure. Conclusions and Relevance The results of this cohort study provide tumor control outcomes for radiologically growing VS treated with radiotherapy using several clinically relevant definitions of growth. By focusing exclusively on this rarely isolated subgroup, the findings offer targeted data to potentially inform treatment expectations and future research.
Multiple substance use and the risk of pancreatitis: a systematic review
Adeniran, Esther, Yadav, Dhiraj, Tan, Judy Y. , Lo, Simon K. , Adeniran, Esther A , Jiang, Yi, Han, Samuel , Pandol, Stephen J. , Jeon, Christie Y.

Mayo Clinic

Therapeutic Advances in Gastroenterology | August 25, 2025 | Volume: 18 | Issue: No issue available | Pages: No page available

10.1177/17562848251365030 | PMID 40873658 Get It

Background: The impact of multiple substance use on the risk of pancreatitis remains underexplored. Objective: To systematically review peer-reviewed observational studies assessing the association of multiple substance use with the risk of acute pancreatitis (AP) or chronic pancreatitis (CP) in adults. Design: We conducted a systematic review informed by the Preferred Reporting Items for Systematic Review and Meta-Analyses guideline. Data sources and methods: EMBASE, MEDLINE, and PsycINFO were searched up to March 2024. Reference lists of included studies were reviewed. From 5205 records identified, 181 relevant records were evaluated in full text. Studies evaluating the association of ⩾2 substances, including tobacco, alcohol, cannabis, and illicit substances, with AP or CP were included. Data were extracted by one reviewer, with quality control by a second reviewer. Quality assessments were independently conducted by two reviewers, with differences resolved by a third. Results: Of 11 included studies, 6 investigated AP as the outcome and 5 examined CP. Among AP studies, 5 comparing smoking and alcohol to alcohol-only use showed high heterogeneity ( I 2 = 90.9%), with relative risks (RRs) from 1.40 to 11.40. One study examining cannabis and alcohol versus alcohol found a lower risk of AP in cannabis users. Among CP studies, four comparing smoking and alcohol to alcohol-only use were heterogeneous ( I 2 = 81%) with odds ratios 1.21–31.50. Where examined, smoking increases the risk of AP and CP in a dose-dependent fashion. Heavy alcohol users demonstrated a significant increase in CP risk across all smoking categories in one study. Conclusion: Combined alcohol and tobacco use increases pancreatitis risk compared to single substance use, despite heterogeneity in RRs and exposure definitions. Evidence suggests a dose-dependent impact of smoking on pancreatitis risk when added to alcohol. Studies on the impact of a combination of other substance use on pancreatitis risk are needed. Trial registration (PROSPERO): CRD42024503677.
Physician-in-the-Loop Active Learning in Radiology Artificial Intelligence Workflows: Opportunities, Challenges, and Future Directions
Luo, Monica , Rouzrokh, Pouria, Alberts, Ian L. , Klyuzhin, Ivan S. , Yousefirizi, Fereshteh , Jin, Weina , Alberts, Ian, Gowdy, Claire , Bouchareb, Yassine , Hamarneh, Ghassan , Rahmim, Arman

Mayo Clinic

American Journal of Roentgenology | August 20, 2025 | Volume: 225 | Issue: 5 | Pages: No page available

10.2214/ajr.25.33364 | PMID 40833223 Get It

Recognition and Management of Iatrogenically Induced Opioid Dependence and Withdrawal in Children: Clinical Report
Siegel, Linda, Wilder, Robert T. , Good, Julie , Reigart, J. Routt, Eckstein, Olive S. , Hindman, Diane E., Verhoef, Philip A. , Watt, Kevin , Care, Section on Critical, Hsu, Benson, Huh, Jimmy W. , Lowrie, Lia, Ndely, Simon-Noel, Satchell, Margaret A., Medicine, Section on Anesthesiology and Pain, Chatterjee, Debnath , Diaz, Christina, Drum, Elizabeth T. , Sun, Lena S. , Willer, Brittany L. , Landrigan‐Ossar, Mary, Adler, Adam C. , Goldman, Jennifer L. , Hindman, Diane E., Care, Section on Critical, Ndely, Simon-Noel, Srinivasan, Vijay , Medicine, Section on Anesthesiology and Pain, Long, Justin B.

Mayo Clinic

Pediatrics | August 18, 2025 | Volume: 156 | Issue: 3 | Pages: No page available

10.1542/peds.2025-073169 | PMID 40819838 Get It

Opioids are often prescribed to children for pain relief related to procedures, acute injuries, and chronic conditions. Around-the-clock dosing of opioids can produce physiologic opioid dependence within 5 days. According to a 2001 consensus paper from the American Academy of Pain Medicine, American Pain Society, and American Society of Addiction Medicine, dependence is defined as “a state of adaptation that is manifested by a drug class specific withdrawal syndrome that can be produced by abrupt cessation, rapid dose reduction, decreasing blood level of the drug, or administration of an antagonist.” The experience of children undergoing iatrogenic withdrawal symptoms is variable and may be mild and go unreported or can be severe and even life threatening. Guidance on opioid withdrawal is available only for adults and primarily for adults with substance use disorders. This report will summarize existing literature and provide readers with information on how to screen for symptoms of iatrogenic opioid withdrawal as well as mechanisms for opioid withdrawal prevention.
DNA Immunotherapy ( INO ‐3107) Results in Long‐Term Surgery Reduction in RRP
Belafsky, Peter C. , Best, Simon R. , Friedman, Aaron D. , Lott, David G. , Mau, Ted , Paniello, Randal C. , Pransky, Seth M. , Welsh, Christopher, Slog, Stefani A., Gillespie, Elisabeth, Dallas, Michael, Morrow, Matthew P. , Skolnik, Jeffrey , Best, Simon R , Lott, David G , Mau, Ted , Paniello, Randal C , Slog, Stefani A , Amin, Milan R , Klein, Adam M. , Saba, Nabil F. , Welsh, Christopher, Dallas, Michael J.

Mayo Clinic

The Laryngoscope | August 9, 2025 | Volume: 135 | Issue: 11 | Pages: 4287-4295

10.1002/lary.32416 | PMID 40781903 Get It

ABSTRACT Objective To evaluate the long‐term safety and clinical effect of INO‐3107 immunotherapy in adults with recurrent respiratory papillomatosis (RRP). Methods RRP‐002 was a retrospective, observational extension study that followed patients enrolled in the 52‐week RRP‐001 study. Patients with moderate to severe juvenile or adult‐onset RRP who had undergone ≥ 2 surgical interventions in the year preceding dosing were eligible for enrollment in RRP‐001. Participants underwent surgical debulking within 14 days prior to initial dosing and then received INO‐3107 on Day 0, Weeks 3, 6, and 9. Efficacy assessments during RRP‐002 follow‐up were the frequency of surgical interventions and alternative medication use. The safety evaluation included reported serious adverse events (SAEs). Results Twenty‐eight (28) of 32 participants from the 52‐week RRP‐001 study were enrolled in RRP‐002. The median follow‐up time for RRP‐002 was 1.8 years (range: 1.2–2.4 years) for a total median assessment time of 2.8 years (range: 1.0–3.5 years). There were no SAEs or long‐term safety concerns identified. The mean number of surgeries was reduced from 4.1 in the pre‐treatment period to 1.7 in the first year post‐INO‐3107 treatment (Year 1) to 0.9 in the second year (Year 2). The complete response rate (0 surgeries per year) increased from 28% (9/32) in Year 1 to 50% (14/28) in Year 2. Conclusion INO‐3107 is well tolerated and provides a continued clinical effect against HPV‐6 and 11 RRP that results in further reduction of the surgical burden observed in Year 1. These data support the role of INO‐3107 immunotherapy for adult patients with RRP. Level of Evidence: III.
Connectivity as a universal predictor of tau progression in atypical Alzheimer’s disease
Bruin, Hannah de , Groot, Colin , Barthel, Henryk , Bischof, Gérard N. , Boon, Baayla D.C. , Brendel, Matthias , Cash, David M. , Coath, William , Day, Gregory S. , Dyck, Christopher H. van , Fredericks, Carolyn , Fryer, Tim D. , Graff‐Radford, Jonathan , Hobbs, Diana A. , Hoenig, Merle C. , Josephs, Keith A. , Katsumi, Yuta , Joie, Renaud La , Xiong, Chengjie , Malpetti, Maura , McGinnis, Scott M., Mecca, Adam P. , O’Brien, John T. , Putcha, Deepti , Rabinovici, Gil D. , Rahmouni, Nesrine , Rullmann, Michael , Saur, Dorothee , Servaes, Stijn , Sintini, Irene , Stevenson, Jenna , Stomrud, Erik , Strandberg, Olof, Tideman, Pontus , Touroutoglou, Alexandra , Trainer, Anne, Wekselman, Fattin, Weston, Philip S.J. , Whitwell, Jennifer L. , Yong, Keir , de Bruin, Hannah , Brendel, Matthias , Cash, David M , Coath, William , Dickerson, Bradford Clark , van Eimeren, Thilo , van der Flier, Wiesje M , Fredericks, Carolyn A , Gordon, Brian A , Graff-Radford, Jonathan , Grinberg, Lea , Hansson, Oskar , Irwin, David J , Josephs, Keith A , Katsumi, Yuta , La Joie, Renaud , Lee, Edward B , Xiong, Chengjie , Malpetti, Maura , Mohanty, Rosaleena , O'Brien, John Tiernan , Palleis, Carla , Phillips, Jeffrey S , Putcha, Deepti , Rosa-Neto, Pedro , Schott, Jonathan M , Schroeter, Matthias L , Smith, Ruben , Spina, Salvatore , Therriault, Joseph , Whitwell, Jennifer , Yong, Keir X X , Franzmeier, Nicolai , Day, Gregory S , Stomrud, Erik , Rabinovici, Gil D , Blazhenets, Ganna , Boellaard, Ronald , Doering, Elena , Drzezga, Alexander E. , Flier, Wiesje M. van der , Giessen, Elsmarieke van de , Gordon, Brian A. , Grinberg, Lea T. , Hansson, Oskar , Höglinger, Günter U. , Irwin, David J. , Jones, Peter Simon , Lee, Edward B. , Mohanty, Rosaleena , Nasrallah, Ilya M. , O’Dell, Ryan S. , Perneczky, Robert , Rowe, James B. , Sabri, Osama , Schildan, Andreas , Schott, Jonathan M. , Seeley, William W. , Servaes, Stijn , Spina, Salvatore , Visser, Denise , Wolk, David A. , Pijnenburg, Yolande A.L. , Franzmeier, Nicolai , Ossenkoppele, Rik

Mayo Clinic

Brain | August 8, 2025 | Volume: 148 | Issue: 11 | Pages: 3893-3912

10.1093/brain/awaf279 | PMID 40810361 Get It

Abstract The link between regional tau load and clinical manifestation of Alzheimer’s disease (AD) highlights the importance of characterizing spatial tau distribution across disease variants. In typical (memory-predominant) AD, the spatial progression of tau pathology mirrors the functional connections from temporal lobe epicentres. However, given the limited spatial heterogeneity of tau in typical AD, atypical (non-amnestic-predominant) AD variants with distinct tau patterns provide a key opportunity to investigate the universality of connectivity as a scaffold for tau progression. In this large-scale, multicentre study across 14 international sites, we included cross-sectional tau-PET data from 320 individuals with atypical AD (n = 139 posterior cortical atrophy/PCA-AD; n = 103 logopenic variant primary progressive aphasia/lvPPA-AD; n = 35 behavioural variant AD/bvAD; n = 43 corticobasal syndrome/CBS-AD), with a subset of individuals (n = 78) having longitudinal tau-PET data. Additionally, as an independent sample, we included regional post-mortem tau stainings from 93 atypical AD patients from two sites (n = 19 PCA-AD, n = 32 lvPPA-AD, n = 23 bvAD, n = 19 CBS-AD). Gaussian mixture modelling was used to harmonize different tau-PET tracers by transforming tau-PET standardized uptake value ratios to tau positivity probabilities (a uniform scale ranging from 0% to 100%). Using linear regression, we assessed whether brain regions with stronger resting-state functional MRI-based functional connectivity, derived from healthy elderly controls in the Alzheimer’s Disease Neuroimaging Initiative (ADNI), showed greater covariance in cross-sectional and longitudinal tau-PET and post-mortem tau pathology. Furthermore, we examined whether functional connectivity of tau-PET epicentres (i.e. the top 5% of regions with the highest baseline tau load) and tau-PET accumulation epicentres (i.e. the top 5% of regions with the highest tau accumulation rates) was associated with cross-sectional and longitudinal tau patterns. Our findings show that tau-PET epicentres aligned with clinical variants, e.g. a visual network predominant pattern in PCA-AD (‘visual AD’) and left-hemispheric temporal predominance, particularly within the language network, in lvPPA-AD (‘language AD’). Moreover, more strongly functionally connected regions showed correlated concurrent tau-PET levels (confirmed with post-mortem data) and tau-PET accumulation rates. The functional connectivity profile of tau-PET epicentres and accumulation epicentres corresponded to tau-PET progression patterns, with higher tau-PET levels and accumulation rates in functionally close regions, and lower tau-PET levels and accumulation rates in functionally distant regions. Our data are consistent with the hypothesis that tau propagation occurs along functional connections originating from local epicentres, across all AD clinical variants. Since tau proteinopathy is a major driver of neurodegeneration and cognitive decline, this finding may advance personalized medicine and participant-specific end points in clinical trials.
Standardized Clinical Terms and Definitions for Interstitial Lung Disease: A Consensus Statement from the Fleischner Society
Ryerson, Christopher J. , Bankier, Alexander A. , Beasley, Mary Beth , Brown, Kevin M. , Colby, Thomas V. , Cottin, Vincent , Galvin, Jeffrey R. , Hariri, Lida P. , Johkoh, Takeshi , Lee, Ho Yun , Leung, Ann N. , Lynch, David A. , Müller, Néstor L. , Raoof, Suhail, Remy-Jardin, Martine , Ryu, Jay H. , Sholl, Lynette M. , Sverzellati, Nicola , Walsh, Simon , Wells, Athol U. , Bankier, Alexander , Colby, Thomas , Haramati, Linda B , Hariri, Lida P , Inoue, Yoshikazu , Lee, Ho Yun , Leung, Ann , Muller, Nestor , Nicholson, Andrew , Revel, Marie-Pierre , Remy-Jardin, Martine , Richeldi, Luca , Ryu, Jay H , Schiebler, Mark , Sholl, Lynette , White, Charles S , Johannson, Kerri A , Desai, Sujal R. , Haramati, Linda B. , Nicholson, Andrew G. , Richeldi, Luca , Travis, William D.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | August 4, 2025 | Volume: 211 | Issue: 10 | Pages: 1756-1774

10.1164/rccm.202505-1142so | PMID 40758555 Get It

Abstract Background Despite advances in diagnosis and management, the interstitial lung disease (ILD) lexicon is plagued by ambiguous and inconsistent terminology that complicates communication and impedes knowledge generation. The objective of this Fleischner Society Consensus Statement was to produce standardized terminology for ILD multidisciplinary diagnoses and major phenotypes. Methods Interviews with 10 experts were used to identify ILD clinical diagnoses and major phenotypes. The preferred terms for each entity and potential alternatives were identified, alongside the rationale for the preferred term. Entities with more than one potential term were the subject of an online modified Delphi survey posed to the 29 committee members, aiming to achieve consensus. Committee members rated their agreement with the initially preferred term—5 (strongly agree), 4 (agree), 3 (neutral/unsure), 2 (disagree), and 1 (strongly disagree)—with the option to provide additional comments. Median score ≥4 and interquartile range ≤1 were considered consensus agreement. Terms not reaching agreement were discussed by video conference, followed by an additional survey that incorporated feedback. Results From the 60 initial terms, there were two root terms that required upfront consensus before survey initiation (ILD and interstitial pneumonia) and another eight terms that had no alternative suggested by the committee or in the literature. Agreement was met by 47/50 terms (94%) in Round 1 of the survey. The three terms (6%) that did not reach agreement met agreement in Round 2. Conclusions This document provides standardized recommended terms for ILD multidisciplinary diagnoses and major phenotypes that will facilitate communication among clinicians, researchers, patients, and other stakeholders.
Implications and opportunities regarding biological frameworks in overt and prodromal dementia with Lewy bodies
Goldman, Jennifer G. , Leverenz, James B., Blanc‬, ‪Frederic, Halliday, Glenda M. , Kantarci, Kejal, Lewis, Simon J.G. , Medsger, Helen Bundy, O’Brien, John T. , Scholz, Sonja W. , Ikeda, Manabu , Kantarci, Kejal , Blanc, Frédéric , O'Brien, John Tiernan , Halliday, Glenda , Goldman, Jennifer G , Scholz, Sonja W , Lewis, Simon J G , Kantarci, Kejal , Boeve, Bradley F. , Galasko, Douglas , Taylor, John‐Paul , Galvin, James E. , Leverenz, James B. , Lemstra, Afina W. , Leroi, Iracema , Litvan, Irene , Aarsland, Dag , McKeith, Ian G. , Taylor, Angela E.

Mayo Clinic

Alzheimer's & Dementia | July 20, 2025 | Volume: 21 | Issue: 7 | Pages: No page available

10.1002/alz.70470 | PMID 40684248 Get It

Abstract Dementia with Lewy bodies (DLB), a progressive neurodegenerative disease with heterogeneous clinical presentations, greatly impacts patients, caregivers, and society. Despite its frequency, diagnosing and treating DLB remains challenging. Advances in in vivo biomarker assays reflecting underlying pathology are improving disease identification, diagnostic accuracy, and therapeutic development for biologically targeted, disease‐modifying agents. Consequently, definitions of Alzheimer's disease and Parkinson's disease (PD) have shifted to focus on pathological changes occurring before clinical features, with proposed frameworks for detecting pathological amyloid and tau, neurodegeneration, and other markers (National Institute on Aging‐Alzheimer's Association) and alpha‐synucleinopathy and dopaminergic degeneration (Neuronal α‐synuclein Disease Integrated Staging System, SynNeurGe). The biological frameworks, particularly those related to alpha‐synuclein (α‐synuclein), have sparked debate about unifying DLB and PD under a single pathobiologic disease. This paper discusses the implications of these biological frameworks for the DLB community, addressing topics regarding multiple pathologies and neurochemical systems, clinical heterogeneity, and functional impairment, and exploring the potential impact on clinical trials and care. Highlights DLB is a progressive neurodegenerative disease with varied clinical presentations. Diagnosing and treating DLB remains challenging despite its frequency. Biological frameworks are reshaping Alzheimer's and Parkinson's definitions. In vivo biomarkers are improving DLB identification and diagnostic accuracy. Debate exists regarding unifying DLB and Parkinson's under one pathobiology.